Condition (MeSH)
Biotinidase Deficiency
ClinicalTrials.gov lists 5 trials for Biotinidase Deficiency or a narrower condition beneath it. Orpha Labs has the most among industry and government lead sponsors, with 1.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
5 of the 5 trials are tagged with Biotinidase Deficiency itself; the rest are tagged with a narrower condition beneath it.
When did Biotinidase Deficiency trials start? (4)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1/2
- Observational
Top of scale: 2
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2022 | 2 |
| 2021 | 1 |
| 2018 | 1 |
| 2013 | 1 |
No forecast is made for this condition: it averages 0.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 5 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Biotinidase Deficiency trials in? (2)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1/2 | 1 |
| Observational | 4 |
How many Biotinidase Deficiency trials are recruiting? (4)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 1 |
| Active, not recruiting | 1 |
| Completed | 2 |
| Unknown status | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Biotinidase Deficiency trials? (1)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Orpha Labs | 1 |
Prevalence (39)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Biotinidase deficiency | Prevalence at birth | 1-9 / 100 000 | United States | US | Exact |
| Biotinidase deficiency | Prevalence at birth | 1-9 / 100 000 | United States | US | Exact |
| Biotinidase deficiency | Prevalence at birth | 1-9 / 100 000 | United States | US | Unspecified |
| Biotinidase deficiency | Prevalence at birth | 1-9 / 100 000 | Worldwide | Not stated | Unspecified |
| Biotinidase deficiency | Point prevalence | 1-9 / 100 000 | Europe | Not stated | Exact |
Showing 5 of 39 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Biotinidase deficiency | 79241 | Exact | Orphadata Science knowledge files, Product 1 |
| Biotinidase deficiency | 79241 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials, publications, and sub-conditions in mesh.
Not computed for conditions with fewer than 10 trials: drugs tested.